EU medicines regulators look at medtech when forming new strategy
This article was originally published in Clinica
The European Heads of Medicines Agencies, in framing its 2011-2015 strategy, is considering whether there is a place for medical devices regulation in the European medicines network over the next five years. As things stand, the HMA believes that "there should be closer engagement of the HMA group in considering medical devices strategy".
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.